Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droxidopa in Chronic Fatigue Syndrome
NCT00977171Phase 2Terminated
- Sponsor
- Chelsea Therapeutics International, Ltd.
- Start
- Jul 2010
- Primary completion
- Oct 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of droxidopa in myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS), neurally mediated hypotension (NMH), Neurogenic Orthostatic Hypotension (nOH), sponsored by Chelsea Therapeutics International, Ltd.. Started Jul 2010; status: terminated.
02
Drugs
droxidopa
03
Conditions
myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)neurally mediated hypotension (NMH)Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT00977171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977171.